Application of benzyl-4-hydroxy-3,5-dimethoxy benzoate in preparation of drugs for treating or preventing rheumatoid arthritis

Abstract

The invention relates to the field of drugs, and particularly relates to a compound capable of inhibiting proteasomes and preventing and treating rheumatoid arthritis. The compound has the molecular structure of benzyl-4-hydroxy-3,5-dimethoxy benzoate. The compound has the beneficial effects that the compound can be used for treating rheumatoid arthritis, and has potential new drug development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to proteasome inhibiting compounds for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist) as the fi...

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long

Despite this, there are no well-developed proteasome compound inhibitors available for the treatment of rheumatoid arthritis

Images